All endocrine glands are susceptible to neoplastic growth, yet the health consequences of
these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent …

Although usually benign, anterior pituitary tumours occasionally exhibit aggressive
behaviour, with invasion of surrounding tissues, rapid growth, resistance to conventional …

Objective After temozolomide failure, no evidence-based treatment is available for pituitary
carcinomas (PCs) and aggressive pituitary tumors (APTs). To date, only 12 cases treated …

Once temozolomide has failed, there is no recommended treatment option for pituitary
carcinomas and aggressive pituitary tumors. Immune-checkpoint inhibitors (ICIs) represent …

Pituitary adenomas (PAs) are benign lesions; nonetheless, some PAs exhibit aggressive
behaviors, which lead to recurrence. The impact of pituitary dysfunction, invasion-related …

Most pituitary adenomas (PAs) are considered benign tumors, but approximately 0.2% can
present metastasis and are classified as pituitary carcinomas (PCs). Refractory PAs lie …

Pituitary tumors are generally benign, although in rare cases aggressive pituitary tumors
(APTs) and carcinomas present important diagnostic and therapeutic challenges and are …

After temozolomide failure, no evidence-based treatment option is currently available for
aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs). Moreover, once …

Invasiveness is a major predictor of surgical outcome and long-term prognosis in patients
with pituitary adenomas (PAs). We assessed PA invasiveness via radiological, surgical and …

Pituitary tumors are very complex and heterogeneous and have a very wide range of
proliferative and aggressive behaviors, and how to define and classify these tumors remains …